Carcinoma, Ductal, Breast News - LARVOL Sigma

Carcinoma, Ductal, Breast

Welcome, Profile Billing Logout

43 Mechanisms of Action

|||||||||| New P3 trial: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (clinicaltrials.gov) - Apr 21, 2014
P3, N=950, Not yet recruiting, Sponsor: German Breast Group

||||||||||  lapatinib / Generic mfg.
Enrollment change:  Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ (clinicaltrials.gov) -  Apr 6, 2014
P=N/A, N=60, Recruiting,  Sponsor: National Cancer Institute (NCI)
N=120 --> 60

|||||||||| Biomarker, Trial completion, Surgery: Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=35, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=120 --> 60 Active, not recruiting --> Completed

||||||||||  venlafaxine / Generic mfg.
Trial completion:  Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer (clinicaltrials.gov) -  Feb 22, 2014
P=N/A, N=119, Completed,  Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  tamoxifen / Generic mfg.
Trial completion:  Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer (clinicaltrials.gov) -  Feb 22, 2014
P3, N=0, Completed,  Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion:  Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer (clinicaltrials.gov) -  Feb 19, 2014
P3, N=0, Completed,  Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting --> Completed No longer recruiting --> Completed

||||||||||  tamoxifen / Generic mfg.
Trial completion:  S9630, Medroxyprogesterone in Treating Women With Breast Cancer (clinicaltrials.gov) -  Feb 19, 2014
P3, N=313, Completed,  Sponsor: Southwest Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed

|||||||||| Enrollment change, HEOR: Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients (clinicaltrials.gov) - Jan 8, 2014
P=N/A, N=750, Recruiting, Sponsor: University of Washington
No longer recruiting --> Completed N=220 --> 750

||||||||||  carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Surgery, Metastases:  Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer (clinicaltrials.gov) -  Nov 24, 2013
P2, N=31, Completed,  Sponsor: University of Alabama at Birmingham
N=220 --> 750 Active, not recruiting --> Completed

||||||||||  carboplatin / Generic mfg.
Trial completion:  GeparSixto: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (clinicaltrials.gov) -  Nov 17, 2013
P2/3, N=595, Completed,  Sponsor: German Breast Group
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment closed: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Oct 13, 2013
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  atorvastatin / Generic mfg.
Trial completion:  A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer (clinicaltrials.gov) -  Sep 26, 2013
P1, N=66, Completed,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Enrollment change, Metastases:  Biological Therapy in Treating Women With Stage IV Breast Cancer (clinicaltrials.gov) -  Sep 8, 2013
P1/2, N=6, Completed,  Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed N=33 --> 6

||||||||||  Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Trial completion, Metastases:  Biological Therapy in Treating Women With Stage IV Breast Cancer (clinicaltrials.gov) -  Sep 8, 2013
P1/2, N=6, Completed,  Sponsor: Barbara Ann Karmanos Cancer Institute
N=33 --> 6 Active, not recruiting --> Completed

|||||||||| Enrollment change: Radiation Therapy in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) - Aug 18, 2013
P0, N=20, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=100 --> 20

|||||||||| Trial completion: Radiation Therapy in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) - Aug 18, 2013
P0, N=20, Completed, Sponsor: University of California, San Francisco
N=100 --> 20 Active, not recruiting --> Completed

||||||||||  pegylated liposomal doxorubicin / Generic mfg.
Trial completion:  Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) -  Jul 16, 2013
P1, N=20, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Biomarker, Trial withdrawal: Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer (clinicaltrials.gov) - Jul 9, 2013
P=N/A, N=0, Withdrawn, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Completed --> Withdrawn

|||||||||| Enrollment open, Surgery: Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery (clinicaltrials.gov) - May 20, 2013
P2, N=82, Recruiting, Sponsor: Roswell Park Cancer Institute
Completed --> Withdrawn Not yet recruiting --> Recruiting

||||||||||  simvastatin / Generic mfg., anastrozole / Generic mfg.
Trial completion:  Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer (clinicaltrials.gov) -  May 14, 2013
P2, N=11, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  simvastatin / Generic mfg.
Trial completion:  Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer (clinicaltrials.gov) -  May 14, 2013
P2, N=50, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  tamoxifen / Generic mfg.
Enrollment change:  Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer (clinicaltrials.gov) -  May 13, 2013
P=N/A, N=27, Completed,  Sponsor: University of Nebraska
Active, not recruiting --> Completed N=100 --> 27

||||||||||  tamoxifen / Generic mfg.
Trial completion:  Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer (clinicaltrials.gov) -  May 13, 2013
P=N/A, N=27, Completed,  Sponsor: University of Nebraska
N=100 --> 27 Active, not recruiting --> Completed

||||||||||  tamoxifen / Generic mfg.
Enrollment closed:  4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ (clinicaltrials.gov) -  Apr 30, 2013
P2b, N=112, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting

|||||||||| Enrollment change, IO biomarker, Epigenetic controller, Biopsy: Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy (clinicaltrials.gov) - Apr 10, 2013
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Suspended --> Active, not recruiting N=100 --> 66

|||||||||| Enrollment closed, IO biomarker, Epigenetic controller, Biopsy: Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy (clinicaltrials.gov) - Apr 10, 2013
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=100 --> 66 Recruiting --> Active, not recruiting

|||||||||| Biomarker, Enrollment change: Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=50, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting N=20 --> 50

|||||||||| Biomarker, Enrollment open: Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=50, Recruiting, Sponsor: University of Chicago
N=20 --> 50 Active, not recruiting --> Recruiting

|||||||||| IO biomarker, Immunomodulating: Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=20, Recruiting, Sponsor: Medical University of South Carolina

||||||||||  anastrozole / Generic mfg.
Biomarker, Trial completion:  Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer (clinicaltrials.gov) -  Mar 17, 2013
P2, N=54, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  gefitinib / Generic mfg.
Preclinical, Trial termination, Surgery:  Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast (clinicaltrials.gov) -  Feb 21, 2013
P2, N=1, Terminated,  Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Completed --> Terminated; PI left VICC

|||||||||| Clinical: Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=10, Recruiting, Sponsor: University of Chicago

|||||||||| Enrollment change: Fast Spectral Imaging Device for Tumor Margin Mapping (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=54, Completed, Sponsor: Duke University
Completed --> Terminated; PI left VICC N=40 --> 54

|||||||||| Trial completion: Fast Spectral Imaging Device for Tumor Margin Mapping (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=54, Completed, Sponsor: Duke University
N=40 --> 54 Recruiting --> Completed

|||||||||| Trial completion: Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions (clinicaltrials.gov) - Jan 3, 2013
P3, N=331, Completed, Sponsor: Georgetown University
Recruiting --> Completed Withdrawn --> Completed

||||||||||  lapatinib / Generic mfg.
Trial initiation date:  Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ (clinicaltrials.gov) -  Jan 2, 2013
P=N/A, N=60, Recruiting,  Sponsor: National Cancer Institute (NCI)
Withdrawn --> Completed Initiation date: Sep 2007 --> Jan 2008

|||||||||| New P2 trial, Surgery: Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Dec 19, 2012
P2, N=82, Recruiting, Sponsor: Roswell Park Cancer Institute

|||||||||| Trial withdrawal: To Evaluate the Characteristics of a Breast Cancer (clinicaltrials.gov) - Dec 13, 2012
P0, N=0, Withdrawn, Sponsor: Mark Dewhirst
Initiation date: Sep 2007 --> Jan 2008 Not yet recruiting --> Withdrawn

|||||||||| Enrollment change: To Evaluate the Characteristics of a Breast Cancer (clinicaltrials.gov) - Dec 13, 2012
P0, N=0, Withdrawn, Sponsor: Mark Dewhirst
Not yet recruiting --> Withdrawn N=50 --> 0

||||||||||  fluvastatin / Generic mfg.
Biomarker, Enrollment change, IO biomarker, Surgery:  Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (clinicaltrials.gov) -  Dec 11, 2012
P2, N=35, Completed,  Sponsor: University of California, San Francisco
N=50 --> 0 N=60 --> 35

||||||||||  fluvastatin / Generic mfg.
Biomarker, Trial completion, IO biomarker, Surgery:  Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (clinicaltrials.gov) -  Dec 11, 2012
P2, N=35, Completed,  Sponsor: University of California, San Francisco
N=60 --> 35 Recruiting --> Completed

|||||||||| Enrollment change, Surgery: Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Nov 29, 2012
P2, N=711, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Completed N=1000 --> 711

||||||||||  anastrozole / Generic mfg., risedronate / Generic mfg.
Biomarker, Trial withdrawal:  Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS (clinicaltrials.gov) -  Nov 27, 2012
P3, N=0, Withdrawn,  Sponsor: International Breast Cancer Study Group
N=1000 --> 711 Recruiting --> Withdrawn

||||||||||  anastrozole / Generic mfg., risedronate / Generic mfg.
Biomarker, Enrollment change:  Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS (clinicaltrials.gov) -  Nov 27, 2012
P3, N=0, Withdrawn,  Sponsor: International Breast Cancer Study Group
Recruiting --> Withdrawn N=1000 --> 0

||||||||||  ritonavir / Generic mfg.
Biomarker, Enrollment change, Surgery:  Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer (clinicaltrials.gov) -  Nov 26, 2012
P1/2, N=52, Recruiting,  Sponsor: Masonic Cancer Center, University of Minnesota
N=1000 --> 0 N=42 --> 52

|||||||||| HEOR: Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients (clinicaltrials.gov) - Nov 6, 2012
P=N/A, N=750, Recruiting, Sponsor: University of Washington

||||||||||  tamoxifen / Generic mfg.
Trial termination:  Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ (clinicaltrials.gov) -  Nov 5, 2012
P2, N=46, Terminated,  Sponsor: Masonic Cancer Center, University of Minnesota
N=42 --> 52 Active, not recruiting --> Terminated; Unable to recruit further patients.

||||||||||  tamoxifen / Generic mfg.
Enrollment change:  Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ (clinicaltrials.gov) -  Nov 5, 2012
P2, N=46, Terminated,  Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Unable to recruit further patients. N=73 --> 46

||||||||||  ritonavir / Generic mfg.
Biomarker, Enrollment open, Surgery:  Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer (clinicaltrials.gov) -  Nov 5, 2012
P1/2, N=52, Recruiting,  Sponsor: Masonic Cancer Center, University of Minnesota
N=73 --> 46 Active, not recruiting --> Recruiting